Transparency Market Research Reports incorporated a definite business overview and investigation inclines on "Atopic Dermatitis Treatment Market". This report likewise incorporates more illumination about fundamental review of the business including definitions, requisitions and worldwide business sector industry structure.
Atopic
dermatitis (AD) is a type of skin disorder in which the skin becomes dry, itchy
and inflamed. Scratching of the skin leads to redness, swelling, scaling,
cracking, weeping and crusting. Though, this condition is most common in
infants and children, also affects adult population. AD is considered as
idiopathic, a disease without a known cause, and is likely to be caused by both
genetic as well as environmental factors. Many persons with AD have been found
with a family history of atopy. People living in dry climate are more likely to
get affected. Generally, people with AD develop asthma and hay fever.
Browse Full Report with TOC:
Topical
steroids are currently the mainstay of treatment of atopic dermatitis and hold
the largest segment of the overall atopic dermatitis treatment market. A five
minute lukewarm baths followed by the application of a moisturizer is also
beneficial in treating patients suffering from AD. Immunomodulators such as
tacrolimus and Pimecrolimus are too used to treat AD. The global market for
atopic dermatitis treatment will be majorly driven by new product launch in
coming years. The anticipated launch of dupilumab, a monoclonal antibody being
developed by Sanofi and Regeneron Pharmaceuticals, Inc. for treating atopic
diseases is expected to play a major role in driving the growth of atopic
dermatitis treatment market across the globe. Side effects associated with
drugs used in the treatment of AD are one of the major reasons hampering the
market growth. The market offers opportunities for companies engaged in
developing novel systemic therapies as there is a considerable need for
medications with enhanced safety and efficacy profiles.
The
number of patients suffering from atopic dermatitis has significantly increased
during the last three decades. According to the National Eczema Association
(NEA), AD affects nearly 10% to 20% of infants in the U.S. In Asia-Pacific,
India and China are the major countries accounting for a larger proportion of
the total prevalent cases around the globe. Some of the key players operating
in the market for atopic dermatitis are Astellas Pharma, Anacor Pharmaceuticals
Inc., Regeneron Pharmaceuticals, Inc. and Meda AB.
This
research report analyzes this market depending on its market segments, major
geographies, and current market trends. Geographies analyzed under this research
report include
·
North America
·
Asia Pacific
·
Europe
·
Rest of the World
This report provides comprehensive analysis of
·
Market growth drivers
·
Factors limiting market growth
·
Current market trends
·
Market structure
·
Market projections for upcoming years
This
report is a complete study of current trends in the market, industry growth
drivers, and restraints. It provides market projections for the coming years.
It includes analysis of recent developments in technology, Porter’s five force
model analysis and detailed profiles of top industry players. The report also
includes a review of micro and macro factors essential for the existing market
players and new entrants along with detailed value chain analysis.
More Reports on Pharmaceutical Market:
About Us:-
Transparency Market Research (TMR) is a
market intelligence company providing global business research reports and
consulting services. Our exclusive blend of quantitative forecasting and trends
analysis provides forward-looking insights for thousands of decision-makers.
Contact Us
Sheela AK
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
Tel: +1-518-618-1030
Browse
Market Research Report:-
